期刊文献+

原发灶^(18)F-FDG PET/CT肿瘤代谢体积与晚期非小细胞肺癌患者预后的相关性研究 被引量:8

Association between Metabolic Tumor Volume from ^(18)F-FDG PET/CT and Prognosis in Patients with Advanced NSCLC
下载PDF
导出
摘要 目的探讨晚期非小细胞肺癌(NSCLC)原发灶18F-FDG PET/CT肿瘤代谢活性体积(MTV)与预后的关系。资料与方法回顾性分析治疗前行PET/CT检查的110例均经病理或细胞学证实的Ⅲ、Ⅳ期NSCLC患者,所有患者均接受同步放、化综合治疗,治疗后随访2年以上,并用Kaplan-Meier法、Log-rank检验及Cox比例风险模型分析MTV及标准摄取值(SUV)与预后的关系,ROC曲线比较MTV与SUVmax预测患者预后的能力。结果全组患者2年总生存率为20.9%,ROC曲线分析显示,MTV与SUV预测预后的曲线下面积分别为0.649和0.523;MTV≤33.8cm3与MTV>33.8cm3患者2年生存率分别为27.6%和5.9%,差异具有统计学意义(P<0.05);单因素及多因素分析均显示,2年生存率与MTV、临床分期、病理类型有关(P<0.05)。结论晚期NSCLC原发灶MTV与患者的预后相关,MTV较大者,患者的生存期较短。 Purpose To evaluate the correlation between the metabolic tumor volume(MTV) of 18-fluorodeoxyglucose positron emission tomography/computed tomography(18F-FDG PET/CT) of primary lesions and the prognosis in patients with advanced non small cell lung cancer(NSCLC).Materials and methods One hundred and ten patients with advanced NSCLC underwent 18F-FDG PET/CT scan were recruited in this study consecutively from January 2005 to December 2007.All the patients developed NSCLC with pathological stage on III or IV and received treatment by radiation and chemotherapy.A 2-year follow-up was conducted after treatment for all the patients.The survival rate analysis was determined by Kaplan-Meier survival curve and log-rank test.The prognostic significance of MTV,SUVmax,and other clinical-pathological variables were calculated by Cox proportional hazards regression analysis.A time-dependent receiver operating characteristic curve(ROC) was utilized to compare the power of MTV and SUV max in predicting patient’s prognosis.Results The overall two-year-survival of the patients was 20.9% after treatment.On time-dependent ROC analysis,MTV showed greater AUC value as compared to SUVmax in predicting prognosis(0.649 vs.0.523).While the cut-off point of MTV was set as 33.8cm3,a significantly higher 2-year survival rate was observed in patients with smaller MTV as compared to patients with larger MTV(5.9% vs.27.6%,P〈0.05).In the univariate and multivariate analyses,clinical stage,MTV and pathological types of primary tumors were significant predictors for 2-year survival rate.Conclusions The MTV measurement of primary lesions is significantly associated with prognosis in patients with advanced NSCLC.Advanced NSCLC patients with larger MTV may have lower survival rate.
出处 《中国医学影像学杂志》 CSCD 北大核心 2011年第4期252-256,共5页 Chinese Journal of Medical Imaging
基金 山东省自然科学基金(ZR2009CL023)资助
关键词 肺肿瘤 正电子发射断层显像术 体层摄影术 X线计算机 氟脱氧葡萄 糖F18:预后 Lung neoplasms; Positron-emission tomography; Tomography,X-ray computed; Fluorodeoxyglucose F18; Prognosis;
  • 相关文献

参考文献13

  • 1David GP, David H J, Christopher G, et al. American society of clinical oncology treatment of unresectable nonmallcell lung cancer guide line: update 2003. J Clin Oncol, 2004, 22(2): 330-353.
  • 2巩合义,于金明,付政,李宝生,李建彬,刘同海.PET/CT对非小细胞肺癌临床分期及精确放疗计划的影响[J].中华肿瘤杂志,2006,28(1):54-57. 被引量:35
  • 3Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurence, and survival. J Thorac Cardiovasc Surg, 2005, 130(1): 151-159.
  • 4Sasaki R, Komaki R, Macapinlac H, et al. [18F] fluorideoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol, 2005, 23(6): 1136-1143.
  • 5Eschmann SM, Friedel G, Paulsen F, et al. Is standardized (18) F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging, 2006, 33(3): 263-269.
  • 6Davies A, Tan C, Paschalides C, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients. Lung Cancer, 2007, 55(1): 75-78.
  • 7Thomas C, Franck M, Maximilien V, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging, 2010, 37(3): 494-504.
  • 8Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys, 2002, 52(1): 49-57.
  • 9Percy L, Dilani K, Philip W, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Radiation Oncology Biol Phys, 2007, 69(2): 328-333.
  • 10Brown R, Leung J. Glucose transporterers and FDG uptake in untreated primary human NON-small cell lung cancer. Nucl Med, 1999, 40(4): 556-565.

二级参考文献12

  • 1Chapman JD,Bradley JD,Eary JF,et al.Molecular (functional)imaging for radiotherapy applications:an RTOG symposium.Int J Radiat Oncol Biol Phys,2003,55:294-301.
  • 2Ling CC,Humm J,Larson S,et al.Towards multidimensional radiotherapy (MD-CRT):biological imaging and biological conformality.Int J Radiat Oncol Biol Phys,2000,47:551-560.
  • 3Rasch C,Barillot I,Remeijer P,et al.Definition of the prostate in CT and MRI:a multi-observer study.Int J Radiat Ohcol Biol Phys,1999,43:57-66.
  • 4Giraud P,Elles S,Helfre S,et al.Conformal radiotherapy for lung cancer:different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists.Radiother Oncol,2002,62:27-36.
  • 5Senan S,van Sornsen de Koste J,Samson M,et al.Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer.Radiother Oncol,1999,53:247-255.
  • 6Schmid RA,Hautmann H,Poellinger B,et al.Staging of recurrent and advanced lung cancer with 18 F-FDG PET in a coincidence technique (hybrid PET).Nucl Med Commun,2003,24:37-45.
  • 7Erdi YE,Rosenzweig K,Erdi AK,et al.Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET).Radiother Oncol,2002,62:51-60.
  • 8Bury T,Dowlati A,Paulus P,et al.Whole body 18FDG positron emission tomography in the staging of non-small cell lung cancer.Eur Respir J,1997,10:2529-2534.
  • 9Hicks RJ,Kalff V,Mac Manus MP,et al.(18) F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.J Nucl Med,2001,42:1596-1604.
  • 10Mac Manus MP,Wong K,Hicks RJ,et al.Early mortality after radical radiotherapy for non-small cell lung cancer:comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center.Int J Radiat Oncol Biol Phys,2002,52:351-361.

共引文献34

同被引文献67

  • 1何建军.多原发性大肠癌14例报告[J].中国普通外科杂志,2005,14(1):51-53. 被引量:8
  • 2Kuehl H, Veit P, Rosenbaum SJ, et al. Can PET/CT replaceseparate diagnositic CT for cancer imaging? Optimizing CTprotocols for imaging cancers of the chest and abdomen. J NuclMed, 2007, 48(1): 45-57.
  • 3Beasely MB, Brambilla E, Travis WD. The 2004 word healthorganization classification of lung tumors. Semin Roentgenol,2005,40(2): 90-97.
  • 4Fischer BM, Mortensen J. The future in diagnosis and stagingof lung cancer: positron emission tomography. Respiration,2006, 73(3): 267-276.
  • 5Beyer T,Townsend DW, Brun T, et al. A combined PET/CTscanner for clinical oncology. J Nucl Med, 2000, 41(8): 1369-1379.
  • 6Pottgen C,Levegrun S,Theegarten D,et al.Value of 18Ffluoro 2 deoxy-D-glucose positron emission tomography/computed tomography in non-small cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy[J].Clin Cancer Res,2006,12:97-106.
  • 7Cerfolio RJ,Bryant AS,Ojha B.Restaging patients with N2 (stage Ⅲa)non-small cell lung cancer after neoadjuvant chemoradiotherapy:a prospective study[J].J Thorac Cardiovasc Surg,2006,131:1229-1235.
  • 8Weber WA,Petersen V,Schmidt B,et al.Positron emission tompgraphy in non-small-cell lung cancer:prediction of response to chemotherapy by quantitative assessment of glucose use[J].J Clin Oncol,2003,21:2651-2657.
  • 9Costelloe CM,Macapinlac HA,Madewell JE,et al.18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma[J].J Nucl Med,2009,50:340-347.
  • 10Hatt M,Visvikis D,Albarghach NM,et al.Prognostic value of 18F FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology[J].Eur J Nucl Med Mol Imaging,2011,38:1191-1202.

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部